Developer docs
API playgroundTry for free, no card

Search company profiles

Senti Biosciences

Full company profile

uuid00005yg

Namestring
Senti Biosciences
Legal namestring
Senti Biosciences, Inc.
Websiteurl
sentibio.com
Company typeenum
Public
Founded yearint
2016
Descriptiontext

Senti Biosciences is a clinical-stage biotechnology company founded in 2016 by synthetic biology pioneer Tim Lu, headquartered in South San Francisco and publicly traded on Nasdaq under the ticker SNTI following a June 2022 business combination with Dynamics Special Purpose Corp. The company develops next-generation cell and gene therapies for cancer using its proprietary Gene Circuit Technology Platform, which programs cells (both NK and T cells) with biological logic to sense disease inputs, compute decisions, and selectively respond. Core platform components include Logic Gating (Boolean OR/NOT gates), Multi-Arming (multi-pathway targeting within a single allogeneic product), Regulator Dial (small-molecule-controlled expression), Smart Sensor (microenvironment-responsive activation), and Calibrated-Release IL-15 (engineered cytokine release for cell persistence).

Senti Bio's lead product candidate, SENTI-202, is a first-in-class off-the-shelf Logic-Gated CAR-NK cell therapy featuring an OR-gate CAR targeting CD33 and/or FLT3, a NOT-gate CAR protecting healthy bone marrow cells expressing EMCN, and calibrated-release IL-15. It is being evaluated in a global Phase 1 trial (NCT06325748) at multiple sites in the United States and Australia for adults with relapsed/refractory acute myeloid leukemia (AML), with potential expansion into myelodysplastic syndrome (MDS) and pediatric AML. Phase 1 data reported a 50% composite complete remission rate in Donor X-derived NK cells versus 12.5% in non-Donor X, and 42% CR at the recommended Phase 2 dose, with all CR patients MRD-negative and remissions extending beyond 21 months. SENTI-202 received FDA Orphan Drug Designation in June 2025 and FDA Regenerative Medicine Advanced Therapy (RMAT) designation in December 2025. The pipeline also includes an undisclosed solid tumor gene-circuit CAR program in discovery.

The company is pre-revenue, with Q4 2025 reported revenue of approximately $22,000 and FY 2025 net loss of $61.4 million. The intended revenue model is one-time product sales of off-the-shelf allogeneic cell therapies upon regulatory approval, supplemented in the interim by capital markets financings (SPAC merger, PIPE, convertible notes) and non-dilutive grants (notably an $8 million CIRM grant plus a $1 million milestone tranche). Patients currently access SENTI-202 exclusively through company-sponsored clinical trials; commercialization is planned on an off-the-shelf basis with traditional pharmaceutical distribution. Key recent financing includes a $50.6 million PIPE in December 2024 and a $40 million senior secured convertible note facility from Celadon Partners SPV 24 (with up to $60 million in CVRs) signed in April 2026, alongside a holding company reorganization in April 2026 creating Senti Biosciences Holdings, Inc.

Short descriptiontext

Senti Biosciences is a clinical-stage biotech developing off-the-shelf CAR-NK and CAR-T cell therapies engineered with proprietary Gene Circuits for cancer, with lead candidate SENTI-202 in a global Phase 1 trial for relapsed/refractory AML.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSouth San Francisco, United States
HQ citystring
South San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cell and gene therapy, car-nk cell therapy, synthetic biology platform, gene circuit technology, cancer immunotherapy
Industry3 codes
PRIMARYHLAAABAD
NK Cell Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAACAF
Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Cancer Cell Therapy
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Cell and Gene Therapy Development / Future Commercialization
TypeOne Time License
Description

As a clinical-stage biotechnology company, Senti Biosciences currently has no revenue. The company is developing cell therapies engineered with Gene Circuits targeting liquid and solid tumors. If SENTI-202 or other pipeline candidates receive regulatory approval, the company would generate revenue from product sales of off-the-shelf CAR-NK cell therapies.

stocktitan.net
2Strategic Financing and Grants
TypeLicensing Royalties
Description

The company raises capital through public market financings, convertible note facilities, grants (CIRM), and business combinations to fund R&D operations. Revenue from therapeutic commercialization is the intended long-term revenue stream.

stocktitan.net
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Senti Biosciences develops gene circuit-enhanced cell and gene therapies for cancer, with its lead candidate SENTI-202 being a first-in-class off-the-shelf Logic-Gated CAR-NK cell therapy for relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome. The company's wholly-owned pipeline is built on a proprietary Gene Circuit Technology Platform that programs therapeutic cells with biological logic (OR/NOT gates, multi-arming, regulator dial, smart sensor modules) to selectively kill cancer cells while sparing healthy tissue, validated in both NK and T cells.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 50% composite complete remission rate in patients receiving Donor X-derived NK cells vs. 12.5% for non-Donor X
+4 more records
Product overview1 text field

Senti Biosciences is a clinical-stage biotechnology company with a proprietary Gene Circuit Technology Platform for developing next-generation cell and gene therapies. The company's wholly-owned pipeline centers on SENTI-202, a first-in-class off-the-shelf Logic-Gated CAR-NK cell therapy for acute myeloid leukemia and myelodysplastic syndrome, which incorporates OR GATE and NOT GATE gene circuits for precise cancer cell targeting while sparing healthy cells. The platform also includes discovery-stage programs for solid tumors. Gene Circuits can be applied to both NK and T cells, allowing optimal cell type selection for each indication.

Product and service3 records
1SENTI-202
CategoryOncology cell therapy product candidate
Description

First-in-class off-the-shelf Logic-Gated selective CD33 OR FLT3 NOT EMCN CAR-NK cell therapy for the treatment of relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Combines an OR GATE CAR targeting CD33 and/or FLT3, a NOT GATE CAR protecting healthy cells expressing EMCN, and calibrated-release IL-15 for enhanced NK cell persistence and activity. Investigational; accessed via Phase 1 clinical trial enrollment.

2Gene Circuit Technology Platform
CategoryCell therapy engineering platform
Description

Proprietary synthetic biology platform that programs next-generation cell and gene therapies by engineering Gene Circuits into therapeutic cells, enabling precision targeting of diseased cells while sparing healthy cells. Incorporates Logic Gating, Multi-Arming, Regulator Dial, and Smart Sensor modules. Validated clinically and preclinically in both NK and T cells. Underpins Senti's pipeline and is available for indication selection across oncology and other disease areas.

3Undisclosed Solid Tumor Program
CategoryOncology cell therapy product candidate
Description

Discovery-stage gene circuit-enhanced CAR cell therapy program targeting solid tumors. Investigational; not yet in clinical trials.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeOthers
Description

SENTI-202 Phase 1 clinical trial is being conducted at multiple clinical sites across the United States and Australia. Principal investigators include those from Sarah Cannon Research Institute, MD Anderson Cancer Center, and other leading hematology/oncology research institutions.

2Healthy Adult Donors for NK Cell Sourcing
Strategic tierCoreTypeOthers
Description

SENTI-202 is manufactured using peripheral blood NK cells from selected healthy adult donors. The company has established donor selection criteria, identifying a 'Donor X' phenotype that correlates with significantly improved efficacy (50% CR rate vs. 12.5%). Donor-derived NK cells enable scalable off-the-shelf manufacturing.

sentibio.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Develops off-the-shelf iPSC-derived NK and T-cell therapies for cancer. Closely comparable allogeneic platform with a similar focus on scalable, multiplexed engineered cell therapies in heme and solid tumors.

TypeDirect peer
Description

Clinical-stage biotech developing allogeneic gamma-delta CAR-T and CAR-NK cell therapies for cancer. Comparable off-the-shelf cell therapy format with overlapping heme and solid tumor indications.

TypeDirect peer
Description

Clinical-stage allogeneic CAR-T and NK cell therapy developer using CRISPR-based genome editing. Comparable gene-edited, off-the-shelf cell therapy approach with shared regulatory pathway and indication overlap.

TypeDirect peer
Description

Develops iPSC-derived allogeneic cell therapies (NK and T cells) engineered with multiple modalities including gene editing. Highly comparable platform model targeting hematologic malignancies and solid tumors.

TypeDirect peer
Description

Pioneer in allogeneic CAR-T cell therapies for hematologic cancers. Comparable off-the-shelf cell therapy model targeting similar oncology patient populations and clinical-stage regulatory milestones.

TypeDirect peer
Description

Clinical-stage biotech developing allogeneic CAR-NK cell therapies for hematologic malignancies and solid tumors. Most direct competitor to Senti's CAR-NK approach, including overlapping NK cell engineering and oncology indications.

TypeBroad incumbent
Description

Leading gene-editing company developing Cas9-based ex vivo cell therapies including allogeneic CAR-T programs. Compares as a broader, well-capitalized incumbent with overlapping gene-editing cell therapy capabilities.

TypeDirect peer
Description

Clinical-stage gene-edited allogeneic CAR-T cell therapy developer using TALEN-based editing. Operates in the same allogeneic engineered cell therapy space with similar platform-level differentiation.

TypeEmerging player
Description

Develops base-editing and ex vivo cell therapies, including gene-edited CAR-T programs. Comparable as a programmable gene-editing platform applied to engineered cell therapies, though differentiated by editing chemistry.

TypeRegional player
Description

Clinical-stage gene and cell therapy company with a focus on ultra-rare and oncology indications, including CAR-T programs. Comparable as an engineered cell therapy developer, but with a distinct regulatory and manufacturing platform.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds13 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors39 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Senti Biosciences

Cancer Cell Therapysentibio.com

Senti Biosciences is a clinical-stage biotech developing off-the-shelf CAR-NK and CAR-T cell therapies engineered with proprietary Gene Circuits for cancer, with lead candidate SENTI-202 in a global Phase 1 trial for relapsed/refractory AML.

What Senti Biosciences does

Senti Biosciences is a clinical-stage biotechnology company founded in 2016 by synthetic biology pioneer Tim Lu, headquartered in South San Francisco and publicly traded on Nasdaq under the ticker SNTI following a June 2022 business combination with Dynamics Special Purpose Corp. The company develops next-generation cell and gene therapies for cancer using its proprietary Gene Circuit Technology Platform, which programs cells (both NK and T cells) with biological logic to sense disease inputs, compute decisions, and selectively respond. Core platform components include Logic Gating (Boolean OR/NOT gates), Multi-Arming (multi-pathway targeting within a single allogeneic product), Regulator Dial (small-molecule-controlled expression), Smart Sensor (microenvironment-responsive activation), and Calibrated-Release IL-15 (engineered cytokine release for cell persistence).

Senti Bio's lead product candidate, SENTI-202, is a first-in-class off-the-shelf Logic-Gated CAR-NK cell therapy featuring an OR-gate CAR targeting CD33 and/or FLT3, a NOT-gate CAR protecting healthy bone marrow cells expressing EMCN, and calibrated-release IL-15. It is being evaluated in a global Phase 1 trial (NCT06325748) at multiple sites in the United States and Australia for adults with relapsed/refractory acute myeloid leukemia (AML), with potential expansion into myelodysplastic syndrome (MDS) and pediatric AML. Phase 1 data reported a 50% composite complete remission rate in Donor X-derived NK cells versus 12.5% in non-Donor X, and 42% CR at the recommended Phase 2 dose, with all CR patients MRD-negative and remissions extending beyond 21 months. SENTI-202 received FDA Orphan Drug Designation in June 2025 and FDA Regenerative Medicine Advanced Therapy (RMAT) designation in December 2025. The pipeline also includes an undisclosed solid tumor gene-circuit CAR program in discovery.

The company is pre-revenue, with Q4 2025 reported revenue of approximately $22,000 and FY 2025 net loss of $61.4 million. The intended revenue model is one-time product sales of off-the-shelf allogeneic cell therapies upon regulatory approval, supplemented in the interim by capital markets financings (SPAC merger, PIPE, convertible notes) and non-dilutive grants (notably an $8 million CIRM grant plus a $1 million milestone tranche). Patients currently access SENTI-202 exclusively through company-sponsored clinical trials; commercialization is planned on an off-the-shelf basis with traditional pharmaceutical distribution. Key recent financing includes a $50.6 million PIPE in December 2024 and a $40 million senior secured convertible note facility from Celadon Partners SPV 24 (with up to $60 million in CVRs) signed in April 2026, alongside a holding company reorganization in April 2026 creating Senti Biosciences Holdings, Inc.

Senti Biosciences firmographics

Firmographics
Name
Senti Biosciences
Legal name
Senti Biosciences, Inc.
Website
https://sentibio.com
Company type
Public
Founded year
2016
Operating status
Operating
Headcount range
51–100 employees
Short description
Senti Biosciences is a clinical-stage biotech developing off-the-shelf CAR-NK and CAR-T cell therapies engineered with proprietary Gene Circuits for cancer, with lead candidate SENTI-202 in a global Phase 1 trial for relapsed/refractory AML.
Ownership category
akta.pro rank

Senti Biosciences industry classification

Industry
Product category
Cancer Cell Therapy
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAABAD
NK Cell Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAACAF
Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • Cell and gene therapy
  • Car-nk cell therapy
  • Synthetic biology platform
  • Gene circuit technology
  • Cancer immunotherapy

Where Senti Biosciences is headquartered

Location

Headquarters

HQ city
South San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Senti Biosciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Cell and Gene Therapy Development / Future Commercialization: As a clinical-stage biotechnology company, Senti Biosciences currently has no revenue. The company is developing cell therapies engineered with Gene Circuits targeting liquid and solid tumors. If SENTI-202 or other pipeline candidates receive regulatory approval, the company would generate revenue from product sales of off-the-shelf CAR-NK cell therapies.
  2. Strategic Financing and Grants: The company raises capital through public market financings, convertible note facilities, grants (CIRM), and business combinations to fund R&D operations. Revenue from therapeutic commercialization is the intended long-term revenue stream.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Senti Biosciences product offering

Product offering

Core offering

Senti Biosciences develops gene circuit-enhanced cell and gene therapies for cancer, with its lead candidate SENTI-202 being a first-in-class off-the-shelf Logic-Gated CAR-NK cell therapy for relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome. The company's wholly-owned pipeline is built on a proprietary Gene Circuit Technology Platform that programs therapeutic cells with biological logic (OR/NOT gates, multi-arming, regulator dial, smart sensor modules) to selectively kill cancer cells while sparing healthy tissue, validated in both NK and T cells.

Product overview

Senti Biosciences is a clinical-stage biotechnology company with a proprietary Gene Circuit Technology Platform for developing next-generation cell and gene therapies. The company's wholly-owned pipeline centers on SENTI-202, a first-in-class off-the-shelf Logic-Gated CAR-NK cell therapy for acute myeloid leukemia and myelodysplastic syndrome, which incorporates OR GATE and NOT GATE gene circuits for precise cancer cell targeting while sparing healthy cells. The platform also includes discovery-stage programs for solid tumors. Gene Circuits can be applied to both NK and T cells, allowing optimal cell type selection for each indication.

Differentiator

Problem solved

Functional benefit

Products and services

  • SENTI-202 First-in-class off-the-shelf Logic-Gated selective CD33 OR FLT3 NOT EMCN CAR-NK cell therapy for the treatment of relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Combines an OR GATE CAR targeting CD33 and/or FLT3, a NOT GATE CAR protecting healthy cells expressing EMCN, and calibrated-release IL-15 for enhanced NK cell persistence and activity. Investigational; accessed via Phase 1 clinical trial enrollment.
  • Gene Circuit Technology Platform Proprietary synthetic biology platform that programs next-generation cell and gene therapies by engineering Gene Circuits into therapeutic cells, enabling precision targeting of diseased cells while sparing healthy cells. Incorporates Logic Gating, Multi-Arming, Regulator Dial, and Smart Sensor modules. Validated clinically and preclinically in both NK and T cells. Underpins Senti's pipeline and is available for indication selection across oncology and other disease areas.
  • Undisclosed Solid Tumor Program Discovery-stage gene circuit-enhanced CAR cell therapy program targeting solid tumors. Investigational; not yet in clinical trials.

Quantifiable outcome

  • 50% composite complete remission rate in patients receiving Donor X-derived NK cells vs. 12.5% for non-Donor X
  • +4 more outcomes

Companies that use Senti Biosciences

Customer profile

Segments1 record

Ideal customer profiles3 records

Senti Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Senti Biosciences partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Clinical Trial Sites (US and Australia)coreOthersSENTI-202 Phase 1 clinical trial is being conducted at multiple clinical sites across the United States and Australia. Principal investigators include those from Sarah Cannon Research Institute, MD Anderson Cancer Center, and other leading hematology/oncology research institutions.
  • Healthy Adult Donors for NK Cell SourcingcoreOthersSENTI-202 is manufactured using peripheral blood NK cells from selected healthy adult donors. The company has established donor selection criteria, identifying a 'Donor X' phenotype that correlates with significantly improved efficacy (50% CR rate vs. 12.5%). Donor-derived NK cells enable scalable off-the-shelf manufacturing.

Scale indicators9 records

Recent moves8 records

Expansion highlights6 records

Senti Biosciences competitors and assessment

Company assessment

Direct peers

  • Fate Therapeutics: Develops off-the-shelf iPSC-derived NK and T-cell therapies for cancer. Closely comparable allogeneic platform with a similar focus on scalable, multiplexed engineered cell therapies in heme and solid tumors.
  • Adicet Bio: Clinical-stage biotech developing allogeneic gamma-delta CAR-T and CAR-NK cell therapies for cancer. Comparable off-the-shelf cell therapy format with overlapping heme and solid tumor indications.
  • Caribou Biosciences: Clinical-stage allogeneic CAR-T and NK cell therapy developer using CRISPR-based genome editing. Comparable gene-edited, off-the-shelf cell therapy approach with shared regulatory pathway and indication overlap.
  • Century Therapeutics: Develops iPSC-derived allogeneic cell therapies (NK and T cells) engineered with multiple modalities including gene editing. Highly comparable platform model targeting hematologic malignancies and solid tumors.
  • Allogene Therapeutics: Pioneer in allogeneic CAR-T cell therapies for hematologic cancers. Comparable off-the-shelf cell therapy model targeting similar oncology patient populations and clinical-stage regulatory milestones.
  • Nkarta Therapeutics: Clinical-stage biotech developing allogeneic CAR-NK cell therapies for hematologic malignancies and solid tumors. Most direct competitor to Senti's CAR-NK approach, including overlapping NK cell engineering and oncology indications.
  • Cellectis: Clinical-stage gene-edited allogeneic CAR-T cell therapy developer using TALEN-based editing. Operates in the same allogeneic engineered cell therapy space with similar platform-level differentiation.

Broad incumbents

  • CRISPR Therapeutics: Leading gene-editing company developing Cas9-based ex vivo cell therapies including allogeneic CAR-T programs. Compares as a broader, well-capitalized incumbent with overlapping gene-editing cell therapy capabilities.

Emerging players

  • Beam Therapeutics: Develops base-editing and ex vivo cell therapies, including gene-edited CAR-T programs. Comparable as a programmable gene-editing platform applied to engineered cell therapies, though differentiated by editing chemistry.

Regional players

  • Precigen: Clinical-stage gene and cell therapy company with a focus on ultra-rare and oncology indications, including CAR-T programs. Comparable as an engineered cell therapy developer, but with a distinct regulatory and manufacturing platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Senti Biosciences social profiles

Digital presence

Senti Biosciences compliance and trust

Trust signal

Compliance2 records

Senti Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Senti Biosciences leadership team

Management profile

Number of profiles

Profiles8 records

Senti Biosciences funding detail

Funding detail

Funding overview

Funding rounds13 records

Investors39 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Senti Biosciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Senti Biosciences

What does Senti Biosciences do?

Senti Biosciences develops gene circuit-enhanced cell and gene therapies for cancer, with its lead candidate SENTI-202 being a first-in-class off-the-shelf Logic-Gated CAR-NK cell therapy for relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome. The company's wholly-owned pipeline is built on a proprietary Gene Circuit Technology Platform that programs therapeutic cells with biological logic (OR/NOT gates, multi-arming, regulator dial, smart sensor modules) to selectively kill cancer cells while sparing healthy tissue, validated in both NK and T cells.

Is Senti Biosciences a public or private company?

Senti Biosciences is a public company. It is classified as public and is currently operating.

When was Senti Biosciences founded?

Senti Biosciences was founded in 2016. It employs 51 to 100 people.

Where is Senti Biosciences based?

Senti Biosciences is headquartered in South San Francisco, United States, in the North America region.

How does Senti Biosciences make money?

Two revenue lines are on record. Cell and Gene Therapy Development / Future Commercialization is the primary driver. The others are strategic Financing and Grants.

Who are Senti Biosciences's main competitors?

Direct peers on record are Fate Therapeutics, Adicet Bio, Caribou Biosciences, Century Therapeutics, Allogene Therapeutics, Nkarta Therapeutics and Cellectis. CRISPR Therapeutics is listed as a broad incumbent. Beam Therapeutics is listed as an emerging player. Precigen is listed as a regional player.

Does Senti Biosciences have an API?

No public API is recorded for Senti Biosciences.

What industry is Senti Biosciences in?

Senti Biosciences's product category is Cancer Cell Therapy. Its primary akta.pro industry code is HLAAABAD, NK Cell Therapies, with a secondary code of HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Defense WorldReviewing Senti Biosciences (NASDAQ:SNTI) and Xenon Pharmaceuticals (NASDAQ:XENE)Senti Biosciences and Xenon Pharmaceuticals are compared on valuation, earnings, and analyst ratings. Xenon beats Senti on 8 of 14 factors, with a lower P/E ratio and higher institutional ownership. Analysts see Senti with a 10,244% upside versus Xenon's 88%.American Banking and Market NewsContrasting Senti Biosciences (NASDAQ:SNTI) and Xenon Pharmaceuticals (NASDAQ:XENE)Senti Biosciences and Xenon Pharmaceuticals are compared on valuation, profitability, and analyst ratings. Xenon trades at a lower P/E ratio and has higher institutional ownership, while Senti has higher earnings and a higher price target. Analysts favor Senti due to its higher probable upside.TradingViewSenti Bio announces 1-for-33 reverse stock splitSenti Biosciences Holdings announced a one-for-thirty-three reverse stock split of its common stock, effective November 18, 2026, with trading on a split-adjusted basis on Nasdaq starting November 19, 2026. The split will reduce outstanding shares from about 85.7 million to approximately 2.6 million.Defense WorldRhythm Pharmaceuticals (NASDAQ:RYTM) & Senti Biosciences (NASDAQ:SNTI) Head to Head SurveySenti Biosciences and Rhythm Pharmaceuticals are compared on analyst ratings, profitability, and valuation. Senti has a higher consensus target price ($9.00 vs $142.00) and beats Rhythm on 8 of 14 factors, but Rhythm trades at a lower P/E ratio.Dealroom.coSenti Biosciences lines up $4.55M equity lifeline from Celadon affiliateSenti Biosciences secured a $4.55 million equity commitment from CPIF II-9 Limited, a Celadon affiliate, to fund operations through late 2027. The capital is structured in five quarterly tranches, with payments starting at $1.8 million in December 2026. The funding supports its gene circuit pipeline, including SENTI-202, which reported encouraging Phase 1 results.American Banking and Market NewsCelldex Therapeutics (NASDAQ:CLDX) vs. Senti Biosciences (NASDAQ:SNTI) Critical SurveyCelldex Therapeutics beats Senti Biosciences on 7 of 13 factors, including profitability and valuation. Celldex trades at a lower price-to-earnings ratio and has a lower beta, while Senti shows higher potential upside. Analysts favor Senti due to its higher possible upside.American Banking and Market NewsReviewing Senti Biosciences (NASDAQ:SNTI) & Regeneron Pharmaceuticals (NASDAQ:REGN)A comparison of Regeneron Pharmaceuticals and Senti Biosciences evaluates institutional ownership, analyst ratings, valuation, and profitability. Regeneron beats Senti on 10 of 14 factors, with higher revenue and earnings, while Senti shows a higher consensus price target and greater upside.Defense WorldHead-To-Head Analysis: Senti Biosciences (NASDAQ:SNTI) and Celldex Therapeutics (NASDAQ:CLDX)Celldex Therapeutics and Senti Biosciences are compared on risk, valuation, and analyst ratings. Celldex has lower revenue but higher earnings and a lower P/E ratio, while Senti has higher potential upside per analysts. Celldex beats Senti on 7 of 13 factors.